Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05480384 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
A Phase 2 study of Esophageal Cancer and Esophageal Adenocarcinoma, sponsored by Brown University.
- Active
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 2
- Study locations
NCT05480384: Active Phase 2 study of Esophageal Cancer and Esophageal Adenocarcinoma, sponsored by Brown University.
NCT05480384 is a Phase 2 study of Esophageal Cancer and Esophageal Adenocarcinoma that is active but no longer recruiting, run by Brown University. The registered enrollment target is 1 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05480384, a Phase 2 study of Esophageal Cancer and Esophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Brown University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 2
- Study locations
Study Summary
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Primary Outcome
Measured by the rates of clinically significant treatment-related grade ≥3 adverse events or pneumonitis.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Trastuzumab deruxtecan
Study Locations (2)
New York
- Weill Cornell Medicine/New York-Presbyterian - New York
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
What the registry record for NCT05480384 still lists
NCT05480384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05480384 reports a single indexed study location in New York, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05480384 about?
NCT05480384 is a clinical study titled "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction". An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
What is the current status of trial NCT05480384?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-07-14. Estimated completion is 2026-01.
What conditions does trial NCT05480384 study?
This clinical trial studies the following conditions: Esophageal Cancer, Esophageal Adenocarcinoma, Gastroesophageal-junction Cancer, HER-2 Protein Overexpression.
What interventions are being tested in trial NCT05480384?
The interventions under investigation include: Nivolumab (DRUG), Trastuzumab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05480384?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05480384 being conducted?
This trial has 2 study locations across New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05480384's enrollment target sits among peer trials
1 124th of 123 the lowest of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI